US2002197266A1PendingUtilityA1

Immunotherapy using interleukin 13 receptor subunit alpha 2

58
Priority: Feb 8, 2000Filed: Feb 8, 2001Published: Dec 26, 2002
Est. expiryFeb 8, 2020(expired)· nominal 20-yr term from priority
Inventors:Waldemar Debinski
C07K 14/7155C07K 16/2866A61K 2039/53A61K 2039/545A61K 2039/505A61P 35/00A61P 43/00A61P 35/04A61P 25/00A61K 39/001184A61K 2039/5156
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13Rα2 in the subject. A composition for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes an isolated agent that can stimulate immune response against IL-13α2.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2, the method comprising the steps of: 
 (a) formulating an anti-cancer vaccine outside of the subject, the vaccine comprising an agent that can stimulate an immune response against IL-13Rα2 when administered to an animal; and  
 (b) administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13Rα2 in the subject.  
 
     
     
         2 . The method of  claim 1 , wherein the agent that can stimulate an immune response against IL-13Rox2 comprises a peptide comprising at least seven contiguous amino acids of SEQ ID NO:1.  
     
     
         3 . The method of  claim 1 , wherein the agent that can stimulate an immune response against IL-13R.α2 is a protein comprising the amino acid sequence of SEQ ID NO:1.  
     
     
         4 . The method  claim 1 , wherein the vaccine further comprises an adjuvant.  
     
     
         5 . The method of  claim 4 , wherein the adjuvant comprises a substance selected from the group consisting of: an aluminum salt; an oil-in-water emulsion; a composition comprising saponin; a composition comprising a bacterial protein; and a cytokine.  
     
     
         6 . The method of  claim 4 , wherein step (b) of administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13Rα2 in the subject comprises administering the vaccine in at least a first dose and a second dose, wherein said first dose is administered to the subject at least 24 hours before said second dose is administered to the subject.  
     
     
         7 . The method of  claim 1 , wherein the agent that can stimulate an immune response against IL-13Rα2 comprises a nucleic acid that encodes a peptide comprising at least seven contiguous amino acids of SEQ ID NO:1.  
     
     
         8 . The method of  claim 7 , wherein the nucleic acid is a naked DNA.  
     
     
         9 . The method of  claim 7 , wherein the nucleic acid is incorporated into an expression vector.  
     
     
         10 . The method of  claim 1 , wherein the agent that can stimulate an immune response against IL-13Rα2 comprises a cell expressing a peptide comprising at least seven contiguous amino acids of SEQ ID NO:1.  
     
     
         11 . The method of  claim 10 , wherein the peptide comprising at least seven contiguous amino acids of SEQ ID NO:1 is a protein comprising the amino acid sequence of SEQ ID NO:1.  
     
     
         12 . The method of  claim 1 , wherein the agent that can stimulate an immune response against IL-13Rα2 comprises a cell into which has been introduced a purified nucleic acid that encodes a peptide comprising at least seven contiguous amino acids of SEQ ID NO:1.  
     
     
         13 . The method of  claim 1 , further comprising the step of providing a subject having or at risk for developing a cancer having cells expressing IL-13Rα2.  
     
     
         14 . The method of  claim 13 , wherein the cells expressing IL-13Rβα2 are glioma cells.  
     
     
         15 . The method of  claim 13 , wherein the subject is a human being.  
     
     
         16 . A composition for stimulating an immune response against IL-13Rα2 when administered to an animal, the composition comprising: 
 (a) an isolated agent that can stimulate an immune response against IL-13Rα2 when administered to an animal; and  
 (b) a pharmaceutically acceptable carrier.  
 
     
     
         17 . The composition of  claim 16 , wherein the agent that can stimulate an immune response against IL-13Rα2 when administered to an animal comprises a peptide comprising at least seven contiguous amino acids of SEQ ID NO:1.  
     
     
         18 . The composition of  claim 17 , wherein the peptide comprising at least seven contiguous amino acids of SEQ ID NO:1 is a protein comprising the amino acid sequence of SEQ ID NO:1.  
     
     
         19 . The composition of  claim 17 , wherein the composition further comprises an adjuvant.  
     
     
         20 . The composition of  claim 19 , wherein the adjuvant comprises a substance selected from the group consisting of: an aluminum salt; an oil-in-water emulsion; a composition comprising saponin; a composition comprising a bacterial protein; and a cytokine.  
     
     
         21 . The composition of  claim 20 , wherein the agent that can stimulate an immune response against IL-13Rα2 when administered to an animal comprises a nucleic acid that encodes a peptide comprising at least seven contiguous amino acids of SEQ ID NO:1.  
     
     
         22 . The composition of  claim 21 , wherein the nucleic acid is a naked DNA.  
     
     
         23 . The composition of  claim 21 , wherein the nucleic acid is incorporated into an expression vector.  
     
     
         24 . The composition of  claim 20 , wherein the agent that can stimulate an immune response against IL-13Rα2 comprises a cell expressing a peptide comprising at least seven contiguous amino acids of SEQ ID NO:1.  
     
     
         25 . The method of  claim 24 , wherein the peptide comprising at least seven contiguous amino acids of SEQ ID NO:1 is a protein comprising the amino acid sequence of SEQ ID NO:1.  
     
     
         26 . The composition of  claim 25 , wherein the agent that can stimulate an immune response against IL-13Rα2 comprises a cell into which has been introduced a purified nucleic acid that encodes a peptide comprising at least seven contiguous amino acids of SEQ ID NO:1.  
     
     
         27 . A method for directing an antibody to cells expressing IL-13RU,2 in a subject, the method comprising the steps of: 
 (a) formulating a pharmaceutical composition outside of a subject, the pharmaceutical composition comprising an antibody that specifically binds IL-13Rα2 and a pharmaceutically acceptable carrier; and    (b) administering the pharmaceutical composition to the subject in an amount sufficient to allow the antibody to specifically bind to the cells expressing IL-13Rα2 in the subject.    
     
     
         28 . The method of  claim 27 , wherein the antibody is a monoclonal antibody.  
     
     
         29 . The method of  claim 27 , wherein the antibody is a polyclonal antibody.  
     
     
         30 . A pharmaceutical composition comprising an antibody that specifically binds IL-13Rα2 and a pharmaceutically acceptable carrier.  
     
     
         31 . The pharmaceutical composition of claim  30 , wherein the antibody is a monoclonal antibody.  
     
     
         32 . The pharmaceutical composition of claim  30 , wherein the antibody is a polyclonal antibody.

Join the waitlist — get patent alerts

Track US2002197266A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.